l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway

Olivia J. Robertson-Gray, Sarah K. Walsh, Erik Ryberg, Ann Cathrine Jönsson-Rylander, Christopher Lipina, Cherry L. Wainwright

Research output: Contribution to journalArticle

12 Downloads (Pure)

Abstract

The phospholipid l-α-lysophosphatidylinositol (LPI), an endogenous ligand for GPR55, is elevated in patients with acute coronary syndrome, and a GPR55 antagonist cannabidiol (CBD) reduces experimental ischemia/reperfusion (I/R) injury. While LPI activates multiple signaling pathways, little is known about which ones are important in cardiomyocytes. In this study we explored whether activation of the Rho kinase/ROCK/p38 MAPK pathway is responsible for LPI-induced extension of I/R injury. Using a high-throughput screening method (dynamic mass redistribution; DMR), mouse- and human-induced pluripotent stem cell (iPSC) cardiomyocytes exposed to LPI were shown to exhibit a rapid, sustained, and concentration-dependent (1 nmol L−1-30 μmol L−1) cellular response. Y-27632 (ROCK inhibitor; 10 & 50 μmol L−1) and CBD (1 μmol L−1) both abolished the DMR response to LPI (10 μmol L−1). In murine iPSC cardiomyocytes, LPI-induced ROCK and p38 MAPK phosphorylation, both of which were prevented by Y-27632 and CBD, but did not induce JNK activation or cleavage of caspase-3. In hearts isolated from wild type (WT) mice subjected to 30 minutes global I/R, LPI (10 μmol L−1) administered via the coronary circulation increased infarct size when applied prior to ischemia onset, but not when given at the time of reperfusion. The exacerbation of tissue injury by LPI was not seen in hearts from GPR55−/− mice or in the presence of Y-27632, confirming that injury is mediated via the GPR55/ROCK/p38 MAPK pathway. These findings suggest that raised levels of LPI in the vicinity of a developing infarct may worsen the outcome of AMI.

Original languageEnglish
Article numbere00487
Pages (from-to)1-12
Number of pages12
JournalPharmacology Research and Perspectives
Volume7
Issue number3
Early online date24 May 2019
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Myocardial Reperfusion Injury
Reperfusion Injury
Myocardial Ischemia
Cannabidiol
p38 Mitogen-Activated Protein Kinases
Cardiac Myocytes
Induced Pluripotent Stem Cells
Reperfusion
Ischemia
High-Throughput Screening Assays
lysophosphatidylinositol
rho-Associated Kinases
Coronary Circulation
Wounds and Injuries
Acute Coronary Syndrome
Caspase 3
Phospholipids
Phosphorylation
Ligands

Keywords

  • cell signaling
  • GPR55
  • ischemia/reperfusion injury
  • lysophosphatidylinositol
  • rho kinase

Cite this

Robertson-Gray, Olivia J. ; Walsh, Sarah K. ; Ryberg, Erik ; Jönsson-Rylander, Ann Cathrine ; Lipina, Christopher ; Wainwright, Cherry L. / l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway. In: Pharmacology Research and Perspectives. 2019 ; Vol. 7, No. 3. pp. 1-12.
@article{939317c165874252996cd11c7795f3ee,
title = "l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway",
abstract = "The phospholipid l-α-lysophosphatidylinositol (LPI), an endogenous ligand for GPR55, is elevated in patients with acute coronary syndrome, and a GPR55 antagonist cannabidiol (CBD) reduces experimental ischemia/reperfusion (I/R) injury. While LPI activates multiple signaling pathways, little is known about which ones are important in cardiomyocytes. In this study we explored whether activation of the Rho kinase/ROCK/p38 MAPK pathway is responsible for LPI-induced extension of I/R injury. Using a high-throughput screening method (dynamic mass redistribution; DMR), mouse- and human-induced pluripotent stem cell (iPSC) cardiomyocytes exposed to LPI were shown to exhibit a rapid, sustained, and concentration-dependent (1 nmol L−1-30 μmol L−1) cellular response. Y-27632 (ROCK inhibitor; 10 & 50 μmol L−1) and CBD (1 μmol L−1) both abolished the DMR response to LPI (10 μmol L−1). In murine iPSC cardiomyocytes, LPI-induced ROCK and p38 MAPK phosphorylation, both of which were prevented by Y-27632 and CBD, but did not induce JNK activation or cleavage of caspase-3. In hearts isolated from wild type (WT) mice subjected to 30 minutes global I/R, LPI (10 μmol L−1) administered via the coronary circulation increased infarct size when applied prior to ischemia onset, but not when given at the time of reperfusion. The exacerbation of tissue injury by LPI was not seen in hearts from GPR55−/− mice or in the presence of Y-27632, confirming that injury is mediated via the GPR55/ROCK/p38 MAPK pathway. These findings suggest that raised levels of LPI in the vicinity of a developing infarct may worsen the outcome of AMI.",
keywords = "cell signaling, GPR55, ischemia/reperfusion injury, lysophosphatidylinositol, rho kinase",
author = "Robertson-Gray, {Olivia J.} and Walsh, {Sarah K.} and Erik Ryberg and J{\"o}nsson-Rylander, {Ann Cathrine} and Christopher Lipina and Wainwright, {Cherry L.}",
year = "2019",
month = "6",
doi = "10.1002/prp2.487",
language = "English",
volume = "7",
pages = "1--12",
journal = "Pharmacology Research and Perspectives",
issn = "2052-1707",
publisher = "Wiley",
number = "3",

}

l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway. / Robertson-Gray, Olivia J.; Walsh, Sarah K.; Ryberg, Erik; Jönsson-Rylander, Ann Cathrine; Lipina, Christopher; Wainwright, Cherry L.

In: Pharmacology Research and Perspectives, Vol. 7, No. 3, e00487, 06.2019, p. 1-12.

Research output: Contribution to journalArticle

TY - JOUR

T1 - l-α-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway

AU - Robertson-Gray, Olivia J.

AU - Walsh, Sarah K.

AU - Ryberg, Erik

AU - Jönsson-Rylander, Ann Cathrine

AU - Lipina, Christopher

AU - Wainwright, Cherry L.

PY - 2019/6

Y1 - 2019/6

N2 - The phospholipid l-α-lysophosphatidylinositol (LPI), an endogenous ligand for GPR55, is elevated in patients with acute coronary syndrome, and a GPR55 antagonist cannabidiol (CBD) reduces experimental ischemia/reperfusion (I/R) injury. While LPI activates multiple signaling pathways, little is known about which ones are important in cardiomyocytes. In this study we explored whether activation of the Rho kinase/ROCK/p38 MAPK pathway is responsible for LPI-induced extension of I/R injury. Using a high-throughput screening method (dynamic mass redistribution; DMR), mouse- and human-induced pluripotent stem cell (iPSC) cardiomyocytes exposed to LPI were shown to exhibit a rapid, sustained, and concentration-dependent (1 nmol L−1-30 μmol L−1) cellular response. Y-27632 (ROCK inhibitor; 10 & 50 μmol L−1) and CBD (1 μmol L−1) both abolished the DMR response to LPI (10 μmol L−1). In murine iPSC cardiomyocytes, LPI-induced ROCK and p38 MAPK phosphorylation, both of which were prevented by Y-27632 and CBD, but did not induce JNK activation or cleavage of caspase-3. In hearts isolated from wild type (WT) mice subjected to 30 minutes global I/R, LPI (10 μmol L−1) administered via the coronary circulation increased infarct size when applied prior to ischemia onset, but not when given at the time of reperfusion. The exacerbation of tissue injury by LPI was not seen in hearts from GPR55−/− mice or in the presence of Y-27632, confirming that injury is mediated via the GPR55/ROCK/p38 MAPK pathway. These findings suggest that raised levels of LPI in the vicinity of a developing infarct may worsen the outcome of AMI.

AB - The phospholipid l-α-lysophosphatidylinositol (LPI), an endogenous ligand for GPR55, is elevated in patients with acute coronary syndrome, and a GPR55 antagonist cannabidiol (CBD) reduces experimental ischemia/reperfusion (I/R) injury. While LPI activates multiple signaling pathways, little is known about which ones are important in cardiomyocytes. In this study we explored whether activation of the Rho kinase/ROCK/p38 MAPK pathway is responsible for LPI-induced extension of I/R injury. Using a high-throughput screening method (dynamic mass redistribution; DMR), mouse- and human-induced pluripotent stem cell (iPSC) cardiomyocytes exposed to LPI were shown to exhibit a rapid, sustained, and concentration-dependent (1 nmol L−1-30 μmol L−1) cellular response. Y-27632 (ROCK inhibitor; 10 & 50 μmol L−1) and CBD (1 μmol L−1) both abolished the DMR response to LPI (10 μmol L−1). In murine iPSC cardiomyocytes, LPI-induced ROCK and p38 MAPK phosphorylation, both of which were prevented by Y-27632 and CBD, but did not induce JNK activation or cleavage of caspase-3. In hearts isolated from wild type (WT) mice subjected to 30 minutes global I/R, LPI (10 μmol L−1) administered via the coronary circulation increased infarct size when applied prior to ischemia onset, but not when given at the time of reperfusion. The exacerbation of tissue injury by LPI was not seen in hearts from GPR55−/− mice or in the presence of Y-27632, confirming that injury is mediated via the GPR55/ROCK/p38 MAPK pathway. These findings suggest that raised levels of LPI in the vicinity of a developing infarct may worsen the outcome of AMI.

KW - cell signaling

KW - GPR55

KW - ischemia/reperfusion injury

KW - lysophosphatidylinositol

KW - rho kinase

UR - http://www.scopus.com/inward/record.url?scp=85067035629&partnerID=8YFLogxK

U2 - 10.1002/prp2.487

DO - 10.1002/prp2.487

M3 - Article

VL - 7

SP - 1

EP - 12

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

SN - 2052-1707

IS - 3

M1 - e00487

ER -